BRPI0418765A - composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástese de células tumorais, método de tratar carcinomas, método de tratar uma doença pró-droga, método de inibir trombose - Google Patents
composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástese de células tumorais, método de tratar carcinomas, método de tratar uma doença pró-droga, método de inibir tromboseInfo
- Publication number
- BRPI0418765A BRPI0418765A BRPI0418765-2A BRPI0418765A BRPI0418765A BR PI0418765 A BRPI0418765 A BR PI0418765A BR PI0418765 A BRPI0418765 A BR PI0418765A BR PI0418765 A BRPI0418765 A BR PI0418765A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibiting
- treating
- tgf
- compound
- pharmaceutical composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 12
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 2
- 208000007536 Thrombosis Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 3
- 201000009030 Carcinoma Diseases 0.000 title 1
- 206010027476 Metastases Diseases 0.000 title 1
- 238000009825 accumulation Methods 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyridine Chemical class C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 abstract 1
- 102100034134 Activin receptor type-1B Human genes 0.000 abstract 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 abstract 1
- 108010015920 Type I Activin Receptors Proteins 0.000 abstract 1
- 102000002138 Type I Activin Receptors Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
Abstract
COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO DE INIBIR O TGF-<225>, MéTODO DE REDUZIR O ACúMULO DE EXCESSO DE MATRIZ EXTRACELULAR, MéTODO DE INIBIR METáSTASE DE CéLULAS TUMORAIS, MéTODO DE TRATAR CARCINOMAS, MéTODO DE TRATAR UMA DOENçA, PRó-DROGA, MéTODO DE INIBIR TROMBOSE. Esta invenção refere-se a imidazóis 2-piridil substituídos que são inibidores de transformação de crescimento fator-<225> (TGF-<225>) receptor tipo I (ALK5) e/ou o receptor ativina tipo I (ALK4), através de métodos de seu preparo e seu uso na medicina, especificamente no tratamento e prevenção de um estágio de doença rnediado por esses receptores.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040027591A KR100749566B1 (ko) | 2004-04-21 | 2004-04-21 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| KR10-2004-0027591 | 2004-04-21 | ||
| PCT/KR2004/002891 WO2005103028A1 (en) | 2004-04-21 | 2004-11-09 | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0418765A true BRPI0418765A (pt) | 2007-10-09 |
| BRPI0418765B1 BRPI0418765B1 (pt) | 2019-06-04 |
| BRPI0418765B8 BRPI0418765B8 (pt) | 2021-05-25 |
Family
ID=35196912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418765A BRPI0418765B8 (pt) | 2004-04-21 | 2004-11-09 | composto da fórmula (i) e composição farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7407958B2 (pt) |
| EP (1) | EP1620426A1 (pt) |
| JP (1) | JP4678540B2 (pt) |
| KR (1) | KR100749566B1 (pt) |
| CN (1) | CN1972921B (pt) |
| AU (1) | AU2004318777B2 (pt) |
| BR (1) | BRPI0418765B8 (pt) |
| CA (1) | CA2564442C (pt) |
| IL (1) | IL178757A (pt) |
| MX (1) | MXPA06012096A (pt) |
| NO (1) | NO20064771L (pt) |
| RU (1) | RU2348626C2 (pt) |
| WO (1) | WO2005103028A1 (pt) |
| ZA (1) | ZA200609626B (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410146B2 (en) * | 2004-04-21 | 2013-04-02 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| US8420685B2 (en) * | 2004-04-21 | 2013-04-16 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| US20080319012A1 (en) * | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| TR201901929T4 (tr) | 2005-02-08 | 2019-03-21 | Genzyme Corp | TGFBeta'ya antikorlar. |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| WO2009115572A2 (en) * | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| WO2009146301A1 (en) * | 2008-05-27 | 2009-12-03 | Yale University | TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE |
| US20100087486A1 (en) * | 2008-05-30 | 2010-04-08 | Hiroshi Nakamura | Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| WO2013078286A1 (en) | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
| RU2475243C1 (ru) * | 2012-02-16 | 2013-02-20 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | Средство, обладающее антигипертензивной активностью |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| CN110066277B (zh) * | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| CN112266378B (zh) * | 2020-11-09 | 2021-10-12 | 延边大学 | 含吲唑结构的咪唑类衍生物及其制备方法和应用 |
| US12240830B2 (en) * | 2021-08-13 | 2025-03-04 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds and use thereof |
| CN115747214B (zh) * | 2022-07-12 | 2025-11-18 | 安徽理工大学 | Mlph基因在制备治疗尘肺病药物中的应用 |
| CN121712526A (zh) | 2023-06-13 | 2026-03-20 | 辛瑟斯治疗股份有限公司 | 抗cd5抗体及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| DK0786455T3 (da) * | 1994-09-26 | 2004-03-29 | Shionogi & Co | Imidazolderivater |
| US5965583A (en) * | 1997-04-24 | 1999-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory disease |
| DE60001229T2 (de) * | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
| CO5271680A1 (es) * | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| EP1391452A4 (en) | 2001-05-25 | 2005-10-26 | Mochida Pharm Co Ltd | 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT |
| JP2003040888A (ja) * | 2001-07-30 | 2003-02-13 | Sankyo Co Ltd | イミダゾール誘導体 |
| GB0218079D0 (en) * | 2002-08-03 | 2002-09-11 | Boatman Peter J | A pipe and pipe assembly |
| MXPA05002981A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf). |
| US7250434B2 (en) * | 2003-12-22 | 2007-07-31 | Janssen Pharmaceutica N.V. | CCK-1 receptor modulators |
-
2004
- 2004-04-21 KR KR1020040027591A patent/KR100749566B1/ko not_active Expired - Fee Related
- 2004-11-08 US US10/983,227 patent/US7407958B2/en not_active Expired - Lifetime
- 2004-11-09 AU AU2004318777A patent/AU2004318777B2/en not_active Ceased
- 2004-11-09 WO PCT/KR2004/002891 patent/WO2005103028A1/en not_active Ceased
- 2004-11-09 JP JP2007509388A patent/JP4678540B2/ja not_active Expired - Fee Related
- 2004-11-09 RU RU2006140989/04A patent/RU2348626C2/ru active
- 2004-11-09 CA CA2564442A patent/CA2564442C/en not_active Expired - Lifetime
- 2004-11-09 CN CN2004800433657A patent/CN1972921B/zh not_active Expired - Fee Related
- 2004-11-09 MX MXPA06012096A patent/MXPA06012096A/es active IP Right Grant
- 2004-11-09 BR BRPI0418765A patent/BRPI0418765B8/pt not_active IP Right Cessation
- 2004-11-09 EP EP04800071A patent/EP1620426A1/en not_active Withdrawn
-
2006
- 2006-10-19 NO NO20064771A patent/NO20064771L/no not_active Application Discontinuation
- 2006-10-19 IL IL178757A patent/IL178757A/en active IP Right Grant
- 2006-11-20 ZA ZA200609626A patent/ZA200609626B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004318777B2 (en) | 2008-10-16 |
| JP4678540B2 (ja) | 2011-04-27 |
| IL178757A (en) | 2011-08-31 |
| EP1620426A1 (en) | 2006-02-01 |
| KR20050102752A (ko) | 2005-10-27 |
| JP2007533734A (ja) | 2007-11-22 |
| RU2006140989A (ru) | 2008-05-27 |
| ZA200609626B (en) | 2008-08-27 |
| AU2004318777A1 (en) | 2005-11-03 |
| CA2564442C (en) | 2011-06-14 |
| RU2348626C2 (ru) | 2009-03-10 |
| MXPA06012096A (es) | 2007-11-20 |
| US7407958B2 (en) | 2008-08-05 |
| US20050261299A1 (en) | 2005-11-24 |
| BRPI0418765B1 (pt) | 2019-06-04 |
| CN1972921B (zh) | 2012-01-04 |
| CN1972921A (zh) | 2007-05-30 |
| IL178757A0 (en) | 2007-02-11 |
| WO2005103028A1 (en) | 2005-11-03 |
| NO20064771L (no) | 2007-01-19 |
| CA2564442A1 (en) | 2005-11-03 |
| BRPI0418765B8 (pt) | 2021-05-25 |
| KR100749566B1 (ko) | 2007-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0418765A (pt) | composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástese de células tumorais, método de tratar carcinomas, método de tratar uma doença pró-droga, método de inibir trombose | |
| CY1123625T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
| BRPI0805826A2 (pt) | compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento | |
| TN2009000225A1 (en) | Compounds and compositions as protein kinase kinase inhibitors | |
| UA100227C2 (uk) | Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування | |
| MY148427A (en) | Compounds and compositions as protein kinase inhibitors | |
| MX2009012066A (es) | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. | |
| CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
| NO20084396L (no) | Kombinasjonsterapi | |
| ECSP10010034A (es) | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
| NO20093009L (no) | Kondensert ring heterocykel kinase modulatorer | |
| ATE411323T1 (de) | Cgrp-rezeptorantagonisten | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| EA201170590A1 (ru) | Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения | |
| NO20074911L (no) | Behandling av benforstyrrelser | |
| NO20090608L (no) | Tyrosinkinaseinhibitorer | |
| NO20091864L (no) | Forbindelser for inhibering av mitotisk progresjon | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| MX2009004745A (es) | Derivados de 1,2,3-triazol como inhibidores del receptor sigma. | |
| BRPI0514736A (pt) | inibidores do receptor sigma | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| MX2009004623A (es) | Imidazopiridazinas como inhibidores de la lipido cinasa pi3k. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2260 DE 29/04/2014. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: EWHA UNIVERSITY COLLABORATION FOUNDATION (KR) ; SK |
|
| B25A | Requested transfer of rights approved |
Owner name: EWHA UNIVERSITY COLLABORATION FOUNDATION (KR) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2800 DE 03-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |